Medical College of Wisconsin

Nexus Pharmaceuticals, Inc. Receives FDA Approval for EMERPHED® (ephedrine sulfate injection) Pre-Filled Syringe

Retrieved on: 
Mittwoch, März 1, 2023
FDA, Pharmaceutical, Health, Nexus, Syringe, Medical College of Wisconsin, MCW, Ephedrine, Injection, Pharmacy, Risk, Journal, Patient, Trial of the century, Patent, Food and Drug Administration, US Foods, Multimedia, Medication, United States Patent and Trademark Office, Food, Medical college, Pharmaceutical industry

Nexus Pharmaceuticals, Inc. announced that it has received US Food and Drug Administration (FDA) approval for EMERPHED® (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL single-dose pre-filled syringes.

Key Points: 
  • Nexus Pharmaceuticals, Inc. announced that it has received US Food and Drug Administration (FDA) approval for EMERPHED® (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL single-dose pre-filled syringes.
  • View the full release here: https://www.businesswire.com/news/home/20230301005543/en/
    EMERPHED® (ephedrine sulfate injection) is available in 25mg/5mL and 50mg/10mL single-dose pre-filled syringes.
  • “In 2020, we were the first manufacturer to launch an FDA-approved ephedrine sulfate injection in a ready-to-use vial.
  • Nexus Pharmaceuticals’ EMERPHED® (ephedrine sulfate injection) pre-filled syringe is available immediately in cartons of ten single-dose syringes.

Medical College of Wisconsin Cancer Center Announces New Training Program to Boost Diversity in Cancer Research

Retrieved on: 
Montag, Februar 27, 2023
University of Wisconsin–Milwaukee, Doctor of Philosophy, Cell biology, Cancer, Prostate cancer, MD, MCW, University of Chicago Comprehensive Cancer Center, ACS, Anatomy, Alverno College, Research, Ace Institute of Health Sciences, Partnership, Neuroscience, Mount Mary University, Mentorship, Diversity, American Cancer Society, American Cancer Society Cancer Action Network, Korea Disease Control and Prevention Agency, Medical College of Wisconsin, Science, Student, Incidence, Medical college, Nursing

MILWAUKEE, Feb. 27, 2023 /PRNewswire/ -- The Medical College of Wisconsin (MCW) Cancer Center today announced a new 2-year training program to improve diversity, equity, and inclusion in cancer research. In partnership with Alverno College, Mount Mary University, UW-Milwaukee, and other Wisconsin universities, the program aims to develop a diverse cancer research workforce – one with the potential to impact cancer disparities in eastern Wisconsin.

Key Points: 
  • Effort Aims to Diversify Research Workforce, Address Regional Cancer Disparities
    MILWAUKEE, Feb. 27, 2023 /PRNewswire/ -- The Medical College of Wisconsin (MCW) Cancer Center today announced a new 2-year training program to improve diversity, equity, and inclusion in cancer research.
  • In partnership with Alverno College, Mount Mary University, UW-Milwaukee, and other Wisconsin universities, the program aims to develop a diverse cancer research workforce – one with the potential to impact cancer disparities in eastern Wisconsin.
  • Funded by the American Cancer Society's (ACS) Center for Diversity in Cancer Research Training , the MCW Cancer Center was one of eight institutions selected to offer the post-baccalaureate program which provides underrepresented students in science with an immersive experience that includes hands-on training in cancer research labs, access to research mentors, participation in community outreach efforts, and career development workshops.
  • Student research via MCW's program will focus on the molecular mechanisms of cancer and cancer health disparities, building on nearly 10 years of cancer disparities research at the MCW Cancer Center.

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Retrieved on: 
Donnerstag, Februar 23, 2023
Headache, Knee, Pediatrics, The New England Journal of Medicine, Quality of life, Diagnosis, European Commission, Associate, Priority review, Physician, Chronic pain, Parity, Sri Siddhartha Medical College, Risk, FDA, Patient, Haemophilia, VIII, Ankle, Elbow, Joint, Medical College of Wisconsin, Orphan drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Haemophilia A, ABR, Bleeding, Coagulopathy, Sanofi, Food, Arthralgia, Factor VIII, Pharmaceutical industry, Birth control, EU

The high sustained factor activity levels that can be achieved with ALTUVIIIO have the potential to change the hemophilia landscape.

Key Points: 
  • The high sustained factor activity levels that can be achieved with ALTUVIIIO have the potential to change the hemophilia landscape.
  • For the first time, with a once-weekly dose, powerful bleed protection is a reality for patients.
  • The severity of hemophilia is determined by the level of clotting factor activity in a person’s blood, and there is a negative correlation between risk of bleeding and factor activity levels.
  • By maintaining high levels of factor activity throughout the week, patients can be confident in the bleed protection ALTUVIIIO offers.”
    This is the first approval of ALTUVIIIO.

FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB

Retrieved on: 
Freitag, Februar 24, 2023
Development, Knee, Pediatrics, The New England Journal of Medicine, MD, Diagnosis, European Commission, Associate, Medical Affairs Bureau, Priority review, Pain, Alfa, Sri Siddhartha Medical College, Standard of care, Research and development, FDA, Patient, VIII, Haemophilia A, Ankle, Elbow, Joint, Medical College of Wisconsin, US Foods, Male, Coagulopathy, Bleeding, ABR, Genetic disorder, Haemophilia, Food, Factor VIII, Swedish Orphan Biovitrum, Birth control, Pharmaceutical industry, Sanofi, EU

Haemophilia A is a rare, genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII.

Key Points: 
  • Haemophilia A is a rare, genetic disorder in which the ability of a person's blood to clot is impaired due to a lack of factor VIII.
  • People with haemophilia can experience bleeding episodes that can cause pain, irreversible joint damage and life-threatening haemorrhages.
  • "By maintaining high levels of factor activity throughout the week, patients can be confident in the bleed protection efanesoctocog alfa offers."
  • In adults and adolescents, efanesoctocog alfa had a favourable safety profile and there were no signs of factor VIII inhibitor development.

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

Retrieved on: 
Donnerstag, Januar 26, 2023
Manuscript, American College, Medical College of Wisconsin, PTSD, Federation of European Neuroscience Societies, Neuropathic pain, IND, COVID-19, Substance-related disorder, Biological Psychiatry (journal), Carleton University, Society, Therapy, Medical college, Inhalation, Conference, LSD, Depression, University, Patient, University of California, San Diego, Patent, Partnership, Canadian Association of College and University Student Services, CSE, Anxiety, GMP, FDA, PCT, Coro de la Pontificia Universidad Católica de Puerto Rico, Data analysis, HPV, Wainwright Securities Inc. v. Wall Street Transcript Corp., FENS, Annual conferences, Alpha-2B adrenergic receptor, Research, Toxicology, Pharmaceutical industry, Vaccine, Medical device, Neuroscience

“We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.

Key Points: 
  • “We are very excited to be working with Bloom Burton, Canada’s leading healthcare investment banking firm,” said Ahmad Doroudian, CEO of BetterLife.
  • Development of scaled-up (kg batch size) manufacturing of BetterLife’s proprietary form of 2-bromo-LSD (“BETR-001”) using BetterLife’s proprietary synthetic pathway.
  • The starting material and whole synthetic pathway do not involve any controlled substance and, therefore, are not bound by controlled substance regulations.
  • Scientific presentations on BETR-001 preclinical data were made at the following conferences:
    Canadian Association for Neuroscience (CAN) / May 12-15, 2022 / Toronto, Canada.

Promaxo Announces Appointment of Dr. Prithipal S. Sethi as Chief Medical Officer of Urology

Retrieved on: 
Dienstag, Dezember 20, 2022
Cell and molecular biology, Saint Louis University School of Medicine, MRI, Health, CMO, University of California, Berkeley, Center of excellence, Golden, Patient, AI, American Board of Commissioners for Foreign Missions, University, Medical college, Medical College of Wisconsin, Robotics, Bachelor of Science, Molecular biology, Medical device, Medicine, Urology

OAKLAND, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced the appointment of Dr. Prithipal S. Sethi as Chief Medical Officer (CMO) of Urology.

Key Points: 
  • OAKLAND, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced the appointment of Dr. Prithipal S. Sethi as Chief Medical Officer (CMO) of Urology.
  • Dr. Sethi is a board-certified urologist who has been practicing urology for more than 25 years.
  • “We are excited to have Dr. Sethi join us as our Chief Medical Officer of Urology.
  • Sethi has the clinical experience, proven leadership ability, and key relationships to make a meaningful impact at Promaxo.

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

Retrieved on: 
Samstag, Dezember 10, 2022
Ulcerative colitis, Cell, Assistant, Clinical trial, Degenerative disease, SAN, Inflammation, Alvin J. Siteman Cancer Center, Graft-versus-host disease, Assistant professor, Safety, News, Biotechnology, CRS, Pharmacokinetics, ASH, ORR, Psoriasis, Medical College of Wisconsin, Saint Francis Hospital & Medical Center, Society, Autoimmunity, IND, COR, Patient, Therapy, Pharmaceutical industry, Vaccine, Aluminium

SAN FRANCISCO, Dec. 10, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced the presentation of new data from its completed Phase 1b clinical trial evaluating ALTB-168 in patients with steroid-refractory (SR-aGVHD) or treatment-refractory (TR-aGVHD) acute graft-versus-host-disease at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, La. The data will be presented in a poster by clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical.

Key Points: 
  • The data will be presented in a poster by clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical.
  • “60% of patients with aGVHD do not respond to corticosteroids as first line treatment, and those that do not respond to any treatment have extremely poor outcomes.
  • The clinical results in this indication validated the strategy of targeting PSGL-1 to control chronically active T cell-related immunological disorders and restore immune balance.
  • ALTB-268 has the same mechanism of action as ALTB-168 with a greater potency that allows for subcutaneous delivery enabling pursuit of different indications than ALTB-168.

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

Retrieved on: 
Donnerstag, Dezember 8, 2022
ICES, Ulcerative colitis, Principal investigator, Medical degree, Pancreatic serous cystadenoma, Assistant, Clinical trial, University, Plan, Inflammation, Next Generation, Acute lymphoblastic leukemia, News, ICE, Biotechnology, Thomas Jefferson University, Northwestern University, Medical college, ASH, Medical College of Wisconsin, Immune checkpoint, MD, Psoriasis, Acute myeloid leukemia, Acute leukemia, Oncology, Research, Autoimmunity, Microdeletion syndrome, IND, Apoptosis, GVHD, Society, Internal medicine, Division, Patient, Q&A, Therapy, Vaccine, Hematology

SAN FRANCISCO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, today announced that the company will host a research and development update on its immune checkpoint enhancer platform for T cell mediated immunological diseases on Thursday, December 15, 2022 at 12 p.m. ET.

Key Points: 
  • AltruBio will provide an overview of its immune checkpoint enhancers (ICEs) which downregulate chronically activated T cells by inhibiting T cell effector function, promoting T cell exhaustion and apoptosis.
  • The company will share development plans for next generation immune checkpoint enhancer, ALTB-268, bearing the same mechanism of action with increased potency for subcutaneous administration in ulcerative colitis patients.
  • The company has leveraged its deep understanding of the role PSGL-1 plays as an immune checkpoint regulator protein to develop a platform for T cell mediated immunological diseases.
  • The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

Be The Match BioTherapies® Launches Bioinformatics Consulting Services

Retrieved on: 
Mittwoch, Dezember 14, 2022
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, General Health, Science, MCW, Physician, Genetics, Match, MD, Center for International Blood and Marrow Transplant Research, HCT, HLA, Doctor of Philosophy, Partnership, Histocompatibility, Health, Patient, Science, Genotype, Collection, NMDP, FDA, Medical College of Wisconsin, KIR, Quality of life, Survival, National Marrow Donor Program, Onboarding, Medical college, Dentistry, Pharmaceutical industry, Research

Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services , which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR (Center for International Blood and Marrow Transplant Research).

Key Points: 
  • Be The Match BioTherapies , an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced its new Bioinformatics Consulting Services , which blends the unique expertise, real-world data and assets of Be The Match BioTherapies and the CIBMTR (Center for International Blood and Marrow Transplant Research).
  • Our Bioinformatics Consulting Services operate at the intersection of science and technology, and bridges the transition from cell culture to the clinic.
  • The new Bioinformatics Consulting Services help companies mitigate risk by using data-driven answers to make decisions that maximize clinical success and speed allogeneic therapies to market.
  • The Bioinformatics Consulting Services experts include Martin Maiers, Vice President, Research; Abeer Madbouly, Principal Bioinformatics Scientist; Michael Wright, Scientific Coordinator; Heather Stefanski, MD, PhD, Vice President, Medical Services; and Steve Devine, MD, Chief Medical Officer.

AHW Awards Nearly $1.5 Million in Seed Grants to Advance Health Research and Support Community Health Projects

Retrieved on: 
Mittwoch, Dezember 14, 2022
Faculty, MCW, AHW, Seed, Research, Biomedical Research, Cancer, Trustee, Cardiovascular disease, Community health, Public, Collaboration, Medical College of Wisconsin, MPH, Attention, Health equity, Health, Violence, Health literacy, Medical college, Pharmaceutical industry, Medicine, MD

MILWAUKEE, Dec. 14, 2022 /PRNewswire/ -- The Advancing a Healthier Wisconsin Endowment (AHW) will provide $1,474,350 in funding to 31 projects selected through a competitive application process focused on promising biomedical research and community-based initiatives aimed at improving the health and well-being of Wisconsin residents.

Key Points: 
  • "Our mission at AHW is to serve as a catalyst for positive change in the health of Wisconsin communities," said AHW Director Jesse Ehrenfeld, MD, MPH.
  • Of the 31 proposals approved for funding, 17 represent research projects led by MCW faculty.
  • For more information on projects funded by AHW, including seed grant awards that take effect in January 2023, visit the funded projects page on the AHW website.
  • Since 2004, AHW has invested more than $336 million in 600 health research, workforce development, and community health initiatives statewide.